{
  "symbol": "BYSI",
  "company_name": "Beyondspring Inc",
  "ir_website": "https://beyondspringpharma.com/",
  "structured_data": [
    {
      "section_name": "News Articles",
      "links": [
        {
          "title": "News & Media",
          "url": "https://beyondspringpharma.com/news-media/",
          "content": "[ ![BeyondSpring](/wp-content/uploads/2020/09/BeyondspringLogo-200px.svg) ](https://beyondspringpharma.com/)\n\nSelect Page\n\n  * [About](/who-we_are)\n    * [Who We Are](https://beyondspringpharma.com/who-we_are/)\n    * [Management Team](https://beyondspringpharma.com/management-team/)\n    * [Scientific Advisors](https://beyondspringpharma.com/scientific-advisors/)\n    * [Board of Directors](https://beyondspringpharma.com/board-of-directors/)\n  * [Pipeline & Research](/pipeline/)\n    * [Pipeline](https://beyondspringpharma.com/pipeline/)\n    * [Plinabulin](https://beyondspringpharma.com/pipeline/plinabulin/)\n    * [Protein Degradation](https://beyondspringpharma.com/protein-degradation/)\n    * [Other Pipeline](https://beyondspringpharma.com/other_pipeline/)\n    * [Posters & Publications](https://beyondspringpharma.com/posters-publications/)\n    * [Collaborations](https://beyondspringpharma.com/collaborations/)\n    * [Expanded Access Policy](https://beyondspringpharma.com/expanded-access-policy/)\n  * [NEWS & MEDIA](https://beyondspringpharma.com/news-media/)\n  * [Investors](/stock-overview)\n    * [Stock Overview](https://beyondspringpharma.com/stock-overview/)\n    * [Events & Presentations](https://beyondspringpharma.com/events-presentation/)\n    * [Financials & Filings](https://beyondspringpharma.com/financials-filings/)\n    * [ESG](https://beyondspringpharma.com/esg/)\n    * [Corporate Governance](https://beyondspringpharma.com/corporate-governance/)\n  * [Careers](https://beyondspringpharma.com/careers/)\n  * [Contact Us](https://beyondspringpharma.com/contact-us/)\n\n\n\n![](/wp-content/uploads/2020/08/news-and-media_hero.png)\n\n# NEWS & MEDIA\n\nWe’re not only at the front lines of therapeutic advancement, we’re also continuously making headlines in healthcare, business, and research markets.\n\n## PRESS RELEASES\n\n## [BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting](https://beyondspringpharma.com/beyondspring-presents-updated-efficacy-results-from-a-phase-2-iit-study-of-triple-io-combo-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progressing-on-prior-immune-checkpoint-i/)\n\nNov 11, 2024\n\nIn 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of 11.5 months achieved a DCR of 89.3% and Median PFS of 8.6 months Florham Park, N.J., November 11, 2024 – BeyondSpring Inc. (NASDAQ: BYSI)...\n\n[read more](https://beyondspringpharma.com/beyondspring-presents-updated-efficacy-results-from-a-phase-2-iit-study-of-triple-io-combo-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progressing-on-prior-immune-checkpoint-i/)\n\n## [BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024](https://beyondspringpharma.com/beyondspring-presents-final-data-analysis-of-dublin-3-phase-3-study-in-2l-3l-egfr-wild-type-nsclc-at-esmo-congress-2024/)\n\nSep 16, 2024\n\nPlinabulin/Docetaxel Combination Demonstrated Favorable Benefit/Risk Ratio over Docetaxel Alone: Significant Improvement in Overall Survival, Progression Free Survival, and Objective Response, with additional Significant Reduction of Grade 4 Neutropenia (>80%...\n\n[read more](https://beyondspringpharma.com/beyondspring-presents-final-data-analysis-of-dublin-3-phase-3-study-in-2l-3l-egfr-wild-type-nsclc-at-esmo-congress-2024/)\n\n## [BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024](https://beyondspringpharma.com/beyondspring-presents-efficacy-safety-results-from-a-phase-2-study-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progressing-on-first-line-immune-checkpoint-inhibitors-at-esmo-c/)\n\nSep 16, 2024\n\nMedian PFS at 8.63 months and Disease Control Rate of 89.5% in Previously Treated NSCLC Patients after Progression on PD-1/L1 Monotherapy or in Combination with Platinum Doublet Chemotherapy Florham Park, N.J., September 16, 2024 – BeyondSpring Inc. (NASDAQ: BYSI)...\n\n[read more](https://beyondspringpharma.com/beyondspring-presents-efficacy-safety-results-from-a-phase-2-study-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progressing-on-first-line-immune-checkpoint-inhibitors-at-esmo-c/)\n\n## [BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine](https://beyondspringpharma.com/beyondspring-delivers-oral-presentation-at-islac-2024-world-conference-on-lung-cancer-of-its-lead-anti-cancer-asset-plinabulin-showcasing-positive-final-phase-3-data-in-2l-3l-nsclc-egfr-wild-type-with/)\n\nSep 10, 2024\n\nStatistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk ratio from DUBLIN-3 Phase 3 Study of Plinabulin plus Docetaxel vs. Docetaxel in EGFR Wild-Type NSCLC after Progression on Platinum-based Therapy Plinabulin/Docetaxel...\n\n[read more](https://beyondspringpharma.com/beyondspring-delivers-oral-presentation-at-islac-2024-world-conference-on-lung-cancer-of-its-lead-anti-cancer-asset-plinabulin-showcasing-positive-final-phase-3-data-in-2l-3l-nsclc-egfr-wild-type-with/)\n\n## [BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin](https://beyondspringpharma.com/beyondspring-announces-oral-presentation-at-the-2024-world-conference-on-lung-cancer-and-two-poster-presentations-during-esmo-congress-2024-showcasing-its-lead-anti-cancer-asset-plinabulin/)\n\nSep 3, 2024\n\nFlorham Park, N.J., September 3, 2024 – BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announces that it will have an oral presentation on...\n\n[read more](https://beyondspringpharma.com/beyondspring-announces-oral-presentation-at-the-2024-world-conference-on-lung-cancer-and-two-poster-presentations-during-esmo-congress-2024-showcasing-its-lead-anti-cancer-asset-plinabulin/)\n\n1[2](https://beyondspringpharma.com/news-media/page/2/?et_blog \"Page 2\")[3](https://beyondspringpharma.com/news-media/page/3/?et_blog \"Page 3\")[4](https://beyondspringpharma.com/news-media/page/4/?et_blog \"Page 4\")[5](https://beyondspringpharma.com/news-media/page/5/?et_blog \"Page 5\")...[10](https://beyondspringpharma.com/news-media/page/10/?et_blog \"Page 10\")[20](https://beyondspringpharma.com/news-media/page/20/?et_blog \"Page 20\")...[»](https://beyondspringpharma.com/news-media/page/2/?et_blog)[Last »](https://beyondspringpharma.com/news-media/page/26/?et_blog)\n\n## MEDIA\n\n[![Seeking Alpha: BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC](https://beyondspringpharma.com/wp-content/uploads/2024/09/Snipaste_2024-09-19_14-15-31-400x250.jpg)](https://seekingalpha.com/news/4150143-beyondspring-plinabulin-merck-keytruda-combo-shows-promise-nsclc?source=apple_news%253Anews)\n\n## [Seeking Alpha: BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC](https://seekingalpha.com/news/4150143-beyondspring-plinabulin-merck-keytruda-combo-shows-promise-nsclc?source=apple_news%253Anews)\n\nSep 16, 2024\n\n[read more](https://seekingalpha.com/news/4150143-beyondspring-plinabulin-merck-keytruda-combo-shows-promise-nsclc?source=apple_news%253Anews)\n\n[![Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC](https://beyondspringpharma.com/wp-content/uploads/2024/09/MPT_logo.svg)](https://www.medpagetoday.com/meetingcoverage/iaslc/111890)\n\n## [Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC](https://www.medpagetoday.com/meetingcoverage/iaslc/111890)\n\nSep 10, 2024\n\n[read more](https://www.medpagetoday.com/meetingcoverage/iaslc/111890)\n\n[![IO360: Developing a Molecule to Help Patients Respond to Immunotherapy](https://beyondspringpharma.com/wp-content/uploads/2024/08/IO360-400x224.png)](https://theconferenceforum.org/editorial/developing-a-molecule-to-help-patients-respond-to-immunotherapy)\n\n## [IO360: Developing a Molecule to Help Patients Respond to Immunotherapy](https://theconferenceforum.org/editorial/developing-a-molecule-to-help-patients-respond-to-immunotherapy)\n\nAug 29, 2024\n\n[read more](https://theconferenceforum.org/editorial/developing-a-molecule-to-help-patients-respond-to-immunotherapy)\n\n1[2](https://beyondspringpharma.com/news-media/page/2/?et_blog \"Page 2\")[3](https://beyondspringpharma.com/news-media/page/3/?et_blog \"Page 3\")[4](https://beyondspringpharma.com/news-media/page/4/?et_blog \"Page 4\")[5](https://beyondspringpharma.com/news-media/page/5/?et_blog \"Page 5\")...[»](https://beyondspringpharma.com/news-media/page/2/?et_blog)[Last »](https://beyondspringpharma.com/news-media/page/6/?et_blog)\n\nWe use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.[Ok](#)[Privacy policy](https://beyondspringpharma.com/privacy-policy/)[](javascript:void\\(0\\);)\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Financials & Filings",
          "url": "https://beyondspringpharma.com/financials-filings/",
          "content": "[ ![BeyondSpring](/wp-content/uploads/2020/09/BeyondspringLogo-200px.svg) ](https://beyondspringpharma.com/)\n\nSelect Page\n\n  * [About](/who-we_are)\n    * [Who We Are](https://beyondspringpharma.com/who-we_are/)\n    * [Management Team](https://beyondspringpharma.com/management-team/)\n    * [Scientific Advisors](https://beyondspringpharma.com/scientific-advisors/)\n    * [Board of Directors](https://beyondspringpharma.com/board-of-directors/)\n  * [Pipeline & Research](/pipeline/)\n    * [Pipeline](https://beyondspringpharma.com/pipeline/)\n    * [Plinabulin](https://beyondspringpharma.com/pipeline/plinabulin/)\n    * [Protein Degradation](https://beyondspringpharma.com/protein-degradation/)\n    * [Other Pipeline](https://beyondspringpharma.com/other_pipeline/)\n    * [Posters & Publications](https://beyondspringpharma.com/posters-publications/)\n    * [Collaborations](https://beyondspringpharma.com/collaborations/)\n    * [Expanded Access Policy](https://beyondspringpharma.com/expanded-access-policy/)\n  * [NEWS & MEDIA](https://beyondspringpharma.com/news-media/)\n  * [Investors](/stock-overview)\n    * [Stock Overview](https://beyondspringpharma.com/stock-overview/)\n    * [Events & Presentations](https://beyondspringpharma.com/events-presentation/)\n    * [Financials & Filings](https://beyondspringpharma.com/financials-filings/)\n    * [ESG](https://beyondspringpharma.com/esg/)\n    * [Corporate Governance](https://beyondspringpharma.com/corporate-governance/)\n  * [Careers](https://beyondspringpharma.com/careers/)\n  * [Contact Us](https://beyondspringpharma.com/contact-us/)\n\n\n\n![Financials & Filings](/wp-content/uploads/2020/09/financials_filings.jpg)\n\n# Financials & filings\n\nOur financial reports reflect both our innovative spirit as well as positive growth. To learn more, click on any quarter filing below.\n\n[\n\n  * [Stock Overview](https://beyondspringpharma.com/stock-overview/)\n  * [Events & Presentations](https://beyondspringpharma.com/events-presentation/)\n  * [Financials & Filings](https://beyondspringpharma.com/financials-filings/)\n  * [ESG](https://beyondspringpharma.com/esg/)\n  * [Corporate Governance](https://beyondspringpharma.com/corporate-governance/)\n\n](#)\n\n## Financial reports\n\nFiling Date Description View\n  * August 29, 2024  2024 Second Quarter Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2024/08/2024-08-29_bysi20240208_6k.htm_6k.pdf)\n  * April 29, 2024  2023 Full Year Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2024/04/2024-04-29_bysi20231231_20f.htm_20f.pdf)\n  * February 2, 2024  6-K – Report of foreign issuer [Rules 13a-16 and 15d-16]  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2024/02/2024-02-02_bysi20230522_6k.htm_6k.pdf)\n  * April 18, 2023  2022 Full Year Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2023/04/2023-04-18_bysi20221230_20f.htm_20f.pdf)\n  * February 28, 2023  6-K – Report of foreign issuer [Rules 13a-16 and 15d-16]  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2023/02/2023-02-28_bysi20230223_6k.htm_6k.pdf)\n  * April 14, 2022  2021 Full Year Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2022/04/2022-04-14_bysi20211231_20f.htm_20f.pdf)\n  * December 30, 2021  2021 Third Quarter Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2021/12/2021-12-30_ex_319375.htm_ex99_1.pdf)\n  * September 10, 2021  2021 Second Quarter Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2021/10/2021-09-10_ex_280834.htm_ex99_1.pdf)\n  * June 16, 2021  2021 First Quarter Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2021/10/2021-06-16_brhc10025730_ex99-1.htm_ex99_1.pdf)\n  * April 30, 2021  2020 Full Year Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2021/11/2021-04-30_brhc10020618_20f.htm_20f.pdf)\n  * November 17, 2020  2020 Third Quarter Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-11-17_brhc10017029_ex99-1.htm.pdf)\n  * September 3, 2020  2020 Second Quarter Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-09-03_brhc10014810_ex99-1.htm.pdf)\n  * June 11, 2020  2020 First Quarter Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-06-11_ex99_1.htm.pdf)\n  * April 30, 2020  2019 Full Year Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2021/11/2020-04-30_form20f.htm_20f.pdf)\n  * December 18, 2019  2019 Third Quarter Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-12-18_ex99_1.htm.pdf)\n  * September 18, 2019  2019 Second Quarter Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-09-18_ex99_1.htm.pdf)\n  * April 30, 2019  2018 Full Year Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2021/11/2019-04-30_form20f.htm_20f.pdf)\n  * June 21, 2018  2018 First Quarter Financial Report  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2018-06-21_ex99_1.htm.pdf)\n  * April 3, 2018  2017 Full Year Financial Report  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/11/2018-04-03_form20f.htm_20f.pdf)\n  * November 9, 2017  2017 Third Quarter Financial Report  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2017-11-09_ex99_1.htm.pdf)\n  * August 21, 2017  2017 Second Quarter Financial Report  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2017-08-21_ex99_1.htm.pdf)\n  * May 22, 2017  2017 First Quarter Financial Report  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2017-05-22_s001712x1_ex99-1.htm.pdf)\n  * April 28, 2017  2016 Full Year Financial Report  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/11/2017-04-28_s001637x1_form20-f.htm_20f.pdf)\n  * March 9, 2017  Initial Public Offering Prospectus  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2017-03-09_s001331x19_424b4.htm.pdf)\n\n\n\n## sec filings\n\nChoose from list Annual FilingsCurrent ReportsRegistration Statement FilingsOther\n\n20242023202220212020201920182017\n\nSubmit \n\nFiling Date Form Description Filing Group View\n  * November 14, 2024  SC 13G/A  SC 13G/A [Amend] – Statement of Beneficial Ownership by Certain Investors  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2024/11/2024-11-14_tm2427620d29_sc13ga.htm_sc13ga.pdf)\n  * August 29, 2024  6-K  2024 Second Quarter Financial Report  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2024/08/2024-08-29_bysi20240208_6k.htm_6k.pdf)\n  * August 6, 2024  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2024/08/2024-08-06_ef20033636_6k.htm_6k.pdf)\n  * June 12, 2024  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2024/06/2024-06-12_ny20030251x2_ex5-1.htm_ex5_1.pdf)\n  * June 12, 2024  424B5  Prospectus [Rule 424(b)(5)]  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2024/06/2024-06-12_ny20030965x1_424b5.htm_424b5.pdf)\n  * June 12, 2024  F-3  Registration statement by foreign private issuers  Registration Statement Filings  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2024/06/2024-06-12_ny20030251x1_f3.htm_f3.pdf)\n  * April 29, 2024  20-F  20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]  Annual Filings  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2024/04/2024-04-29_bysi20231231_20f.htm_20f.pdf)\n  * March 18, 2024  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2024/03/2024-03-18_ef20024295_6k.htm_6k.pdf)\n  * February 26, 2024  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2024/02/2024-02-26_ef20022301_6k.htm_6k.pdf)\n  * February 14, 2024  SC 13G/A  SC 13G/A [Amend] – Statement of acquisition of beneficial ownership by individuals  Other  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2024/02/2024-02-14_ef20021715_sc13ga.htm_sc13ga.pdf)\n  * February 14, 2024  SC 13G/A  SC 13G/A [Amend] – Statement of Beneficial Ownership by Certain Investors  Other  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2024/06/2024-02-14_ef20021715_sc13ga.htm_sc13ga.pdf)\n  * February 2, 2024  6-K  6-K – Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2024/02/2024-02-02_bysi20230522_6k.htm_6k.pdf)\n  * January 16, 2024  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2024/01/2024-01-16_ef20018876_6k.htm_6k.pdf)\n  * January 10, 2024  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](/wp-content/uploads/2020/09/PDF_icon.png) ](https://beyondspringpharma.com/wp-content/uploads/2024/01/2024-01-10_ef20018509_ex99-1.htm_ex99_1.pdf)\n  * December 18, 2023  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2023/12/2023-12-18_ef20016864_ex99-1.htm_ex99_1.pdf)\n  * October 30, 2023  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2023/10/2023-10-30_ef20013571_ex99-1.htm_ex99_1.pdf)\n  * October 4, 2023  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2023/10/2023-10-04_ef20011971_ex99-1.htm_ex99_1.pdf)\n  * September 20, 2023  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2023/09/2023-09-20_ef20011014_6-k.htm_6k.pdf)\n  * July 14, 2023  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2023/07/2023-07-14_brhc20055847_6k.htm_6k.pdf)\n  * May 12, 2023  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2023/05/2023-05-12_brhc20052885_6k.htm_6k.pdf)\n  * April 18, 2023  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2023/04/2023-04-18_brhc20051515_6k.htm_6k.pdf)\n  * April 18, 2023  20-F  20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]  Annual Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2023/04/2023-04-18_bysi20221230_20f.htm_20f.pdf)\n  * April 7, 2023  SC 13G/A  SC 13G/A [Amend] – Statement of acquisition of beneficial ownership by individuals  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2023/04/2023-04-07_brhc10051226_sc13ga.htm_sc13ga.pdf)\n  * April 7, 2023  SC 13G/A  SC 13G/A [Amend] – Statement of Beneficial Ownership by Certain Investors  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2024/06/2023-04-07_brhc10051226_sc13ga.htm_sc13ga.pdf)\n  * March 14, 2023  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2023/03/2023-03-14_brhc10049771_6-k.htm_6k.pdf)\n  * February 28, 2023  6-K  6-K – Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2023/02/2023-02-28_bysi20230223_6k.htm_6k.pdf)\n  * February 24, 2023  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2023/02/2023-02-24_brhc10048826_6k.htm_6k.pdf)\n  * February 14, 2023  SC 13G/A  SC 13G/A [Amend] – Statement of acquisition of beneficial ownership by individuals  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2023/02/2023-02-14_ny20007509x1_s13ga.htm_sc13ga.pdf)\n  * February 14, 2023  SC 13G/A  SC 13G/A [Amend] – Statement of Beneficial Ownership by Certain Investors  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2024/06/2023-02-14_ny20007509x1_s13ga.htm_sc13ga.pdf)\n  * January 9, 2023  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2023/01/2023-01-09_brhc10046446_ex99-1.htm_ex99_1.pdf)\n  * December 30, 2022  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2022/12/2022-12-30_brhc10046019_6k.htm_6k.pdf)\n  * November 23, 2022  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2022/11/2022-11-23_brhc10044658_6k.htm_6k.pdf)\n  * August 29, 2022  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2022/08/2022-08-29_brhc10041384_6k.htm_6k.pdf)\n  * June 13, 2022  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2022/06/2022-06-13_brhc10038687_6k.htm_6k.pdf)\n  * June 9, 2022  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2022/06/2022-06-09_brhc10038622_6k.htm_6k.pdf)\n  * April 22, 2022  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2022/04/2022-04-22_brhc10036635_6k.htm_6k.pdf)\n  * April 14, 2022  20-F  20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]  Annual Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2022/04/2022-04-14_bysi20211231_20f.htm_20f.pdf)\n  * February 14, 2022  SC 13G/A  SC 13G/A [Amend] – Statement of acquisition of beneficial ownership by individuals  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2022/02/2022-02-14_brhc10033901_sc13ga.htm_sc13ga.pdf)\n  * February 14, 2022  SC 13G/A  SC 13G/A [Amend] – Statement of Beneficial Ownership by Certain Investors  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2024/06/2022-02-14_BeyondSpring.htm_sc13ga.pdf)\n  * February 11, 2022  SC 13G/A  SC 13G/A [Amend] – Statement of acquisition of beneficial ownership by individuals  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2022/02/2022-02-11_brhc10033802_sc13ga.htm_sc13ga.pdf)\n  * February 11, 2022  SC 13G/A  SC 13G/A [Amend] – Statement of Beneficial Ownership by Certain Investors  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2024/06/2022-02-11_brhc10033802_sc13ga.htm_sc13ga.pdf)\n  * January 11, 2022  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2022/01/2022-01-11_brhc10032765_6k.htm_6k.pdf)\n  * December 30, 2021  6-K  2021 Third Quarter Financial Report  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/12/2021-12-30_ex_319375.htm_ex99_1.pdf)\n  * December 27, 2021  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/12/2021-12-27_brhc10032272_6k.htm_6k.pdf)\n  * December 1, 2021  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/12/2021-12-01_brhc10031401_99-1.htm_ex99_1.pdf)\n  * November 10, 2021  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/11/2021-11-10_brhc10030689_6k.htm_6k.pdf)\n  * September 21, 2021  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/10/2021-09-21_brhc10029110_ex99-1.htm_ex99_1.pdf)\n  * September 10, 2021  6-K  2021 Second Quarter Financial Report  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/10/2021-09-10_ex_280834.htm_ex99_1.pdf)\n  * August 26, 2021  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/10/2021-08-26_brhc10028401_ex99-1.htm_ex99_1.pdf)\n  * August 5, 2021  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/10/2021-08-05_brhc10027672_ex99-1.htm_ex99_1.pdf)\n  * August 4, 2021  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/10/2021-08-04_brhc10027570_ex99-1.htm_ex99_1.pdf)\n  * July 14, 2021  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/10/2021-07-14_brhc10026843_ex99-1.htm_ex99_1.pdf)\n  * July 2, 2021  F-3  Registration statement by foreign private issuers  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/10/2021-07-02_nt10026536x1_f3.htm_f3.pdf)\n  * June 16, 2021  6-K  2021 First Quarter Financial Report  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/10/2021-06-16_brhc10025730_ex99-1.htm_ex99_1.pdf)\n  * April 30, 2021  20-F  20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]  Annual Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/11/2021-04-30_brhc10020618_20f.htm_20f.pdf)\n  * April 1, 2021  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/10/2021-04-01_brhc10022495_ex99-1.htm_ex99_1.pdf)\n  * March 19, 2021  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/10/2021-03-19_brhc10022038_6k.htm_6k.pdf)\n  * March 16, 2021  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/10/2021-03-16_brhc10021809_6k.htm_6k.pdf)\n  * February 16, 2021  SC 13G/A  SC 13G/A [Amend] – Statement of acquisition of beneficial ownership by individuals  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/11/2021-02-16_brhc10020461_sc13ga.htm_sc13ga.pdf)\n  * February 16, 2021  SC 13G/A  SC 13G/A [Amend] – Statement of Beneficial Ownership by Certain Investors  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2024/06/2021-02-16_brhc10020461_sc13ga.htm_sc13ga.pdf)\n  * February 9, 2021  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/10/2021-02-09_nc10019837x1_ex99-3.htm_ex99_3.pdf)\n  * December 18, 2020  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-12-18_nc10018109x1_ex99-1.htm.pdf)\n  * November 23, 2020  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-11-23_nt10017010x4_ex5-1.htm.pdf)\n  * November 19, 2020  424B5  Prospectus [Rule 424(b)(5)]  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-11-19_nt10017010x3_424b5.htm.pdf)\n  * November 17, 2020  6-K  2020 Third Quarter Financial Report  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-11-17_brhc10017029_ex99-1.htm.pdf)\n  * November 17, 2020  424B5  Prospectus [Rule 424(b)(5)]  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-11-17_nt10017010x1_424b5.htm.pdf)\n  * November 16, 2020  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-11-16_nt10017010x2_ex99-1.htm.pdf)\n  * November 13, 2020  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-11-13_brhc10016766_ex99-1.htm.pdf)\n  * November 3, 2020  F-3  Registration statement by foreign private issuers  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-11-03_brhc10016506_f3.htm.pdf)\n  * September 22, 2020  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-09-22_brhc10015353_ex99-1.htm.pdf)\n  * September 3, 2020  6-K  2020 Second Quarter Financial Report  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-09-03_brhc10014810_ex99-1.htm.pdf)\n  * August 19, 2020  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-08-19_brhc10014537_ex99-1.htm.pdf)\n  * July 27, 2020  SC 13D  General statement of acquisition of beneficial ownership  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-07-27_bysi-sc13d_071520.htm.pdf)\n  * July 24, 2020  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-07-24_brhc10013706_ex99-3.htm.pdf)\n  * July 24, 2020  S-8  Securities to be offered to employees in employee benefit plans  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-07-24_forms8.htm.pdf)\n  * June 23, 2020  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-06-23_nt10012779x6_ex10-1.htm.pdf)\n  * June 19, 2020  424B5  Prospectus [Rule 424(b)(5)]  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-06-19_nt10012779x5_424b5.htm.pdf)\n  * June 18, 2020  424B5  Prospectus [Rule 424(b)(5)]  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-06-18_nt10012779x1_424b5.htm.pdf)\n  * June 15, 2020  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-06-15_nt10012779x2_ex99-1.htm.pdf)\n  * June 11, 2020  6-K  2020 First Quarter Financial Report  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-06-11_ex99_1.htm.pdf)\n  * April 30, 2020  20-F  20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]  Annual Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/11/2020-04-30_form20f.htm_20f.pdf)\n  * March 11, 2020  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-03-11_ex99_1.htm.pdf)\n  * February 10, 2020  SC 13G/A  SC 13G/A [Amend] – Statement of acquisition of beneficial ownership by individuals  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-02-10_tm207365d1_sc13ga.htm.pdf)\n  * February 10, 2020  SC 13G/A  SC 13G/A [Amend] – Statement of Beneficial Ownership by Certain Investors  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2024/06/2020-02-10_tm207365d1_sc13ga.htm_sc13ga.pdf)\n  * February 7, 2020  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-02-07_nc10008472x1_ex5-1.htm.pdf)\n  * February 7, 2020  424B5  Prospectus [Rule 424(b)(5)]  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-02-07_nt10008471x1_424b5.htm.pdf)\n  * January 23, 2020  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2020-01-23_exh_991.htm.pdf)\n  * December 18, 2019  6-K  2019 Third Quarter Financial Report  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-12-18_ex99_1.htm.pdf)\n  * October 29, 2019  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-10-29_nt10005441x3_ex5-1.htm.pdf)\n  * October 28, 2019  424B5  Prospectus [Rule 424(b)(5)]  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-10-28_nt10005441x4_424b5.htm.pdf)\n  * October 25, 2019  424B5  Prospectus [Rule 424(b)(5)]  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-10-25_nt10005441x1_424b5.htm.pdf)\n  * October 15, 2019  F-3  Registration statement by foreign private issuers  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-10-15_formf3.htm.pdf)\n  * September 18, 2019  6-K  2019 Second Quarter Financial Report  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-09-18_ex99_1.htm.pdf)\n  * July 19, 2019  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-07-19_nt10003255x3_ex5-1.htm.pdf)\n  * July 18, 2019  424B5  Prospectus [Rule 424(b)(5)]  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-07-18_nt10003255x2_424b5.htm.pdf)\n  * July 16, 2019  424B5  Prospectus [Rule 424(b)(5)]  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-07-16_nt10003255x1_424b5.htm.pdf)\n  * July 10, 2019  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-07-10_ex10_2.htm.pdf)\n  * May 22, 2019  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-05-22_nc10002097x1_ex5-1.htm.pdf)\n  * May 21, 2019  424B5  Prospectus [Rule 424(b)(5)]  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-05-21_nt10001986x1_424b5.htm.pdf)\n  * April 30, 2019  20-F  20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]  Annual Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/11/2019-04-30_form20f.htm_20f.pdf)\n  * February 20, 2019  SC 13G/A  SC 13G/A [Amend] – Statement of acquisition of beneficial ownership by individuals  Other  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2019-02-20_formsc13ga.htm.pdf)\n  * October 23, 2018  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2018-10-23_ex99_2.htm.pdf)\n  * August 1, 2018  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2018-08-01_ex99_1.htm.pdf)\n  * June 21, 2018  6-K  2018 First Quarter Financial Report  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2018-06-21_ex99_1.htm.pdf)\n  * May 30, 2018  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2018-05-30_ex10_4.htm.pdf)\n  * May 29, 2018  424B5  Prospectus [Rule 424(b)(5)]  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2018-05-29_form424b5.htm.pdf)\n  * April 25, 2018  F-3  Registration statement by foreign private issuers  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2018-04-25_formf3.htm.pdf)\n  * April 3, 2018  20-F  20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]  Annual Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/11/2018-04-03_form20f.htm_20f.pdf)\n  * March 27, 2018  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2018-03-27_form6k.htm.pdf)\n  * February 21, 2018  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2018-02-21_form6k.htm.pdf)\n  * January 29, 2018  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2018-01-29_ex99_1.htm.pdf)\n  * November 9, 2017  6-K  2017 Third Quarter Financial Report  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2017-11-09_ex99_1.htm.pdf)\n  * August 21, 2017  6-K  2017 Second Quarter Financial Report  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2017-08-21_ex99_1.htm.pdf)\n  * May 24, 2017  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2017-05-24_s001719x1_ex99-1.htm.pdf)\n  * May 22, 2017  6-K  2017 First Quarter Financial Report  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2017-05-22_s001712x1_ex99-1.htm.pdf)\n  * May 4, 2017  6-K  Report of foreign issuer [Rules 13a-16 and 15d-16]  Current Reports  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2017-05-04_exh_991.htm.pdf)\n  * April 28, 2017  20-F  20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]  Annual Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2021/11/2017-04-28_s001637x1_form20-f.htm_20f.pdf)\n  * March 13, 2017  S-8  Securities to be offered to employees in employee benefit plans  Registration Statement Filings  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2017-03-13_s001331x20_s8.htm.pdf)\n  * March 9, 2017  424B4  Initial Public Offering Prospectus  [ ![PDF icon](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif) ](https://beyondspringpharma.com/wp-content/uploads/2020/12/2017-03-09_s001331x19_424b4.htm.pdf)\n\n\n\nWe use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.[Ok](#)[Privacy policy](https://beyondspringpharma.com/privacy-policy/)[](javascript:void\\(0\\);)\n"
        }
      ]
    },
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://beyondspringpharma.com/news-media/#pressReleases",
          "content": "[ ![BeyondSpring](/wp-content/uploads/2020/09/BeyondspringLogo-200px.svg) ](https://beyondspringpharma.com/)\n\nSelect Page\n\n  * [About](/who-we_are)\n    * [Who We Are](https://beyondspringpharma.com/who-we_are/)\n    * [Management Team](https://beyondspringpharma.com/management-team/)\n    * [Scientific Advisors](https://beyondspringpharma.com/scientific-advisors/)\n    * [Board of Directors](https://beyondspringpharma.com/board-of-directors/)\n  * [Pipeline & Research](/pipeline/)\n    * [Pipeline](https://beyondspringpharma.com/pipeline/)\n    * [Plinabulin](https://beyondspringpharma.com/pipeline/plinabulin/)\n    * [Protein Degradation](https://beyondspringpharma.com/protein-degradation/)\n    * [Other Pipeline](https://beyondspringpharma.com/other_pipeline/)\n    * [Posters & Publications](https://beyondspringpharma.com/posters-publications/)\n    * [Collaborations](https://beyondspringpharma.com/collaborations/)\n    * [Expanded Access Policy](https://beyondspringpharma.com/expanded-access-policy/)\n  * [NEWS & MEDIA](https://beyondspringpharma.com/news-media/)\n  * [Investors](/stock-overview)\n    * [Stock Overview](https://beyondspringpharma.com/stock-overview/)\n    * [Events & Presentations](https://beyondspringpharma.com/events-presentation/)\n    * [Financials & Filings](https://beyondspringpharma.com/financials-filings/)\n    * [ESG](https://beyondspringpharma.com/esg/)\n    * [Corporate Governance](https://beyondspringpharma.com/corporate-governance/)\n  * [Careers](https://beyondspringpharma.com/careers/)\n  * [Contact Us](https://beyondspringpharma.com/contact-us/)\n\n\n\n![](//beyondspringpharma.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif)\n\n# NEWS & MEDIA\n\nWe’re not only at the front lines of therapeutic advancement, we’re also continuously making headlines in healthcare, business, and research markets.\n\n## PRESS RELEASES\n\n## [BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting](https://beyondspringpharma.com/beyondspring-presents-updated-efficacy-results-from-a-phase-2-iit-study-of-triple-io-combo-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progressing-on-prior-immune-checkpoint-i/)\n\nNov 11, 2024\n\nIn 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of 11.5 months achieved a DCR of 89.3% and Median PFS of 8.6 months Florham Park, N.J., November 11, 2024 – BeyondSpring Inc. (NASDAQ: BYSI)...\n\n[read more](https://beyondspringpharma.com/beyondspring-presents-updated-efficacy-results-from-a-phase-2-iit-study-of-triple-io-combo-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progressing-on-prior-immune-checkpoint-i/)\n\n## [BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024](https://beyondspringpharma.com/beyondspring-presents-final-data-analysis-of-dublin-3-phase-3-study-in-2l-3l-egfr-wild-type-nsclc-at-esmo-congress-2024/)\n\nSep 16, 2024\n\nPlinabulin/Docetaxel Combination Demonstrated Favorable Benefit/Risk Ratio over Docetaxel Alone: Significant Improvement in Overall Survival, Progression Free Survival, and Objective Response, with additional Significant Reduction of Grade 4 Neutropenia (>80%...\n\n[read more](https://beyondspringpharma.com/beyondspring-presents-final-data-analysis-of-dublin-3-phase-3-study-in-2l-3l-egfr-wild-type-nsclc-at-esmo-congress-2024/)\n\n## [BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024](https://beyondspringpharma.com/beyondspring-presents-efficacy-safety-results-from-a-phase-2-study-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progressing-on-first-line-immune-checkpoint-inhibitors-at-esmo-c/)\n\nSep 16, 2024\n\nMedian PFS at 8.63 months and Disease Control Rate of 89.5% in Previously Treated NSCLC Patients after Progression on PD-1/L1 Monotherapy or in Combination with Platinum Doublet Chemotherapy Florham Park, N.J., September 16, 2024 – BeyondSpring Inc. (NASDAQ: BYSI)...\n\n[read more](https://beyondspringpharma.com/beyondspring-presents-efficacy-safety-results-from-a-phase-2-study-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progressing-on-first-line-immune-checkpoint-inhibitors-at-esmo-c/)\n\n## [BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine](https://beyondspringpharma.com/beyondspring-delivers-oral-presentation-at-islac-2024-world-conference-on-lung-cancer-of-its-lead-anti-cancer-asset-plinabulin-showcasing-positive-final-phase-3-data-in-2l-3l-nsclc-egfr-wild-type-with/)\n\nSep 10, 2024\n\nStatistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk ratio from DUBLIN-3 Phase 3 Study of Plinabulin plus Docetaxel vs. Docetaxel in EGFR Wild-Type NSCLC after Progression on Platinum-based Therapy Plinabulin/Docetaxel...\n\n[read more](https://beyondspringpharma.com/beyondspring-delivers-oral-presentation-at-islac-2024-world-conference-on-lung-cancer-of-its-lead-anti-cancer-asset-plinabulin-showcasing-positive-final-phase-3-data-in-2l-3l-nsclc-egfr-wild-type-with/)\n\n## [BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin](https://beyondspringpharma.com/beyondspring-announces-oral-presentation-at-the-2024-world-conference-on-lung-cancer-and-two-poster-presentations-during-esmo-congress-2024-showcasing-its-lead-anti-cancer-asset-plinabulin/)\n\nSep 3, 2024\n\nFlorham Park, N.J., September 3, 2024 – BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announces that it will have an oral presentation on...\n\n[read more](https://beyondspringpharma.com/beyondspring-announces-oral-presentation-at-the-2024-world-conference-on-lung-cancer-and-two-poster-presentations-during-esmo-congress-2024-showcasing-its-lead-anti-cancer-asset-plinabulin/)\n\n1[2](https://beyondspringpharma.com/news-media/page/2/?et_blog \"Page 2\")[3](https://beyondspringpharma.com/news-media/page/3/?et_blog \"Page 3\")[4](https://beyondspringpharma.com/news-media/page/4/?et_blog \"Page 4\")[5](https://beyondspringpharma.com/news-media/page/5/?et_blog \"Page 5\")...[10](https://beyondspringpharma.com/news-media/page/10/?et_blog \"Page 10\")[20](https://beyondspringpharma.com/news-media/page/20/?et_blog \"Page 20\")...[»](https://beyondspringpharma.com/news-media/page/2/?et_blog)[Last »](https://beyondspringpharma.com/news-media/page/26/?et_blog)\n\n## MEDIA\n\n[![Seeking Alpha: BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC](https://beyondspringpharma.com/wp-content/uploads/2024/09/Snipaste_2024-09-19_14-15-31-400x250.jpg)](https://seekingalpha.com/news/4150143-beyondspring-plinabulin-merck-keytruda-combo-shows-promise-nsclc?source=apple_news%253Anews)\n\n## [Seeking Alpha: BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC](https://seekingalpha.com/news/4150143-beyondspring-plinabulin-merck-keytruda-combo-shows-promise-nsclc?source=apple_news%253Anews)\n\nSep 16, 2024\n\n[read more](https://seekingalpha.com/news/4150143-beyondspring-plinabulin-merck-keytruda-combo-shows-promise-nsclc?source=apple_news%253Anews)\n\n[![Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC](https://beyondspringpharma.com/wp-content/uploads/2024/09/MPT_logo.svg)](https://www.medpagetoday.com/meetingcoverage/iaslc/111890)\n\n## [Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC](https://www.medpagetoday.com/meetingcoverage/iaslc/111890)\n\nSep 10, 2024\n\n[read more](https://www.medpagetoday.com/meetingcoverage/iaslc/111890)\n\n[![IO360: Developing a Molecule to Help Patients Respond to Immunotherapy](https://beyondspringpharma.com/wp-content/uploads/2024/08/IO360-400x224.png)](https://theconferenceforum.org/editorial/developing-a-molecule-to-help-patients-respond-to-immunotherapy)\n\n## [IO360: Developing a Molecule to Help Patients Respond to Immunotherapy](https://theconferenceforum.org/editorial/developing-a-molecule-to-help-patients-respond-to-immunotherapy)\n\nAug 29, 2024\n\n[read more](https://theconferenceforum.org/editorial/developing-a-molecule-to-help-patients-respond-to-immunotherapy)\n\n1[2](https://beyondspringpharma.com/news-media/page/2/?et_blog \"Page 2\")[3](https://beyondspringpharma.com/news-media/page/3/?et_blog \"Page 3\")[4](https://beyondspringpharma.com/news-media/page/4/?et_blog \"Page 4\")[5](https://beyondspringpharma.com/news-media/page/5/?et_blog \"Page 5\")...[»](https://beyondspringpharma.com/news-media/page/2/?et_blog)[Last »](https://beyondspringpharma.com/news-media/page/6/?et_blog)\n\nWe use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.[Ok](#)[Privacy policy](https://beyondspringpharma.com/privacy-policy/)[](javascript:void\\(0\\);)\n"
        }
      ]
    }
  ]
}